Skip to main content

Search Videos and More

Showing 25 - 36 of 162 results

Previous| 1... 2 | 3 | 4 ...14 |Next

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

In which of your patients with FH do you feel PSCK9 inhibitors will become foundational agents, in conjunction with statins, when tolerated?

In which of your patients with FH do you feel PSCK9 inhibitors will become foundational agents, in conjunction with statins, when tolerated?

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

How do you stratify your patients with known ASCVD to determine their eligibility for PCSK9 inhibitors, and are there some patients that you would characterize as ultra-high risk and, therefore, requiring LDL-C lowering to less than 70 mg/dL?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL?

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL?

Showing 25 - 36 of 162 results

Previous| 1... 2 | 3 | 4 ...14 |Next